转换为长效注射卡博特韦联合利匹韦林对直肠HIV-1 RNA脱落的影响及传播风险意义
一项前瞻性研究分析90名病毒学抑制者从口服ART转为每2月一次肌注CAB/RPV后直肠HIV-1 RNA动态。肌注期间14.7%直肠样本可检出HIV-1 RNA(42.2%参与者),口服ART期间为17.5%(29%参与者);脱落与血浆HIV-1 RNA及直肠RPV浓度无关,与ART前血浆HIV-1 RNA>5 log10相关。
要点
- 肌注CAB/RPV期间直肠HIV-1 RNA脱落常见(14.7%样本,42.2%参与者),口服ART期间亦存在(17.5%样本,29%参与者)。
- 直肠脱落频率和量与是否口服导入无关,与血浆HIV-1 RNA及直肠RPV浓度无相关性。
- 多因素Cox回归显示直肠脱落与ART前血浆HIV-1 RNA>5 log10相关,与CAB/RPV病毒学失败已知预测因素无关。
核心结论
- 每2月一次肌注CAB/RPV治疗期间直肠HIV-1 RNA脱落常见,口服ART期间亦观察到脱落。
- 脱落独立于同期血浆HIV-1 RNA和直肠RPV浓度,与ART前病毒载量相关。
研究设计与样本
- 前瞻性研究,分析90名病毒学抑制者从口服ART转为每2月一次肌注CAB/RPV(伴或不伴口服导入)后9个月随访期内配对血浆和直肠液样本。
- 共分析597份血浆和561份直肠样本,并在384份直肠样本中测定RPV谷浓度。
主要发现
- 肌注CAB/RPV期间14.7%(59/401)直肠样本检出HIV-1 RNA>50(>1.69 log10)拷贝/拭子,涉及42.2%参与者;口服ART期间为17.5%(28/160)直肠样本,涉及29%参与者。
- 肌注期间可检出直肠HIV-1 RNA中位数为362(范围133-2216)拷贝/拭子。
- 伴或不伴口服导入组间直肠脱落频率和量无差异。
- 直肠脱落与可检出血浆HIV-1 RNA无相关性;直肠RPV浓度中位数3.07(四分位距2.83-3.35)log10 ng/拭子,为直肠组织EC90的1.6倍,与直肠HIV-1 RNA水平无相关性。
- 多因素Cox回归中直肠脱落与ART前血浆HIV-1 RNA>5 log10相关,与CAB/RPV病毒学失败的既定预测因素无关。
关键数值与推荐
- 直肠HIV-1 RNA检出阈值定义为>50(>1.69 log10)拷贝/拭子。
- 肌注CAB/RPV期间直肠脱落样本比例14.7%(59/401),参与者比例42.2%;口服ART期间分别为17.5%(28/160)和29%。
- 直肠RPV浓度中位数3.07 log10 ng/拭子,为直肠组织EC90的1.6倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of long-acting injectable cabotegravir plus rilpivirine (CAB/RPV) on rectal human immunodeficiency virus 1 (HIV-1) RNA dynamics and the factors associated with viral shedding remain poorly understood. METHODS: This prospective study evaluated HIV-1 RNA dynamics by analyzing sequential paired plasma and rectal fluid samples from virologically suppressed individuals who transitioned from oral antiretroviral therapy (ART) to every-2-month CAB/RPV (preceded or not by oral lead-in), over a 9-month follow-up period. RPV trough concentrations were measured in 384 rectal samples. RESULTS: In total, 597 plasma and 561 rectal samples from 90 participants were analyzed. HIV-1 RNA >50 (>1.69 log10) copies/swab was detected in 14.7% (59/401) of rectal samples (42.2% of participants) during intramuscular CAB/RPV, and in 17.5% (28/160) of rectal samples (29% of participants) during oral ART. Median detectable rectal HIV-1 RNA level during intramuscular ART was 362 (range, 133-2216) copies/swab. The frequency and quantity of rectal shedding did not differ between groups with/without oral lead-in. No correlation was observed between rectal shedding and detectable plasma HIV-1 RNA. Median rectal RPV concentration was 3.07 (quartile 1-quartile 3, 2.83-3.35) log10 ng/swab, 1.6-fold above the 90% maximum effective concentration (EC90) for rectal tissue, and did not correlate with rectal HIV-1 RNA levels. Rectal shedding was associated with plasma pre-ART HIV-1 RNA >5 log10 in multivariate Cox regression, but was unrelated to established predictors of virological failure with CAB/RPV. CONCLUSIONS: Rectal HIV-1 shedding is common during bimonthly intramuscular CAB/RPV treatment and is also observed with oral ART. Shedding was independent of concurrent plasma HIV-1 RNA and rectal RPV concentrations, and was associated with pre-ART viral load.
引用
- Masiá M, Fernández-González M, Ledesma C, et al. Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk. J Infect Dis. 2025. PMID: 40042896. doi:10.1093/infdis/jiaf117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。